Neurocognitive evaluation of long term survivors of atypical teratoid rhabdoid tumors (ATRT): The Canadian registry experience Journal Articles uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Identity
  •  
  • Additional Document Info
  •  
  • View All
  •  

abstract

  • BackgroundBecause atypical teratoid rhabdoid tumor(ATRT) is a rare disease of infancy carrying a grim prognosis, focus on long‐term outcome, especially neurocognitive remained very limited. With new era of multimodality therapy, an increasing proportion of patients are now long‐term survivors.ProcedureRetrospective review of neuropsychological (NP) status of survivors from the Canadian ATRT registry.ResultsAmong 77 patients diagnosed between 1995–2012, 16(22%) were survivors. Formal NP assessments were available in eight patients. Partial information on academic achievement was available on three additional patients. There were four girls and seven boys diagnosed at a median age of 27.5 months. Seven patients underwent complete resection and three had metastatic disease. All but one received sequential high dose chemotherapy. Five patients received intrathecal chemotherapy. Three patients underwent radiation. Median age at time of formal NP assessment was 7.6 years (3.9–9.8). Full Scale Intellectual Quotient (FSIQ) ranged from less than 50–119 (mean 78). Simple expressive and receptive language appeared relatively preserved. Three recently diagnosed patients (median time assessment from diagnosis 2.6 years (1.6–4.7)) had average to high average FSIQ, academic and visual spatial skills, visual, and verbal memory. Five other patients diagnosed earlier and tested at a median time of 4.9 years (3.3–8.3) post‐diagnosis had a FSIQ ranging from <50 to 71. Approximately 50% of their scores were in the impaired range.ConclusionOverall this cohort appears significantly impaired at school age despite the absence of systematic radiotherapy. Larger series focusing on neurocognitive outcome are needed in the current context where treatment strategies include adjuvant radiation. Pediatr Blood Cancer 2015;62:1265–1269. © 2015 Wiley Periodicals, Inc.

authors

  • Lafay‐Cousin, Lucie
  • Fay‐McClymont, Taryn
  • Johnston, Donna
  • Fryer, Chris
  • Scheinemann, Katrin
  • Fleming, Adam
  • Hukin, Juliette
  • Janzen, Laura
  • Guger, Sharon
  • Strother, Douglas
  • Mabbott, Donald
  • Huang, Annie
  • Bouffet, Eric

publication date

  • July 2015

has subject area